Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.38 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 2/20 | 0.37 |
| ▸ | CTSS | P25774 | 2/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 2/20 | 0.36 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4252098 | 0.91 | CTSS (0.39) | ALDH1A1PKMITGA4ITGB7CTSS | |
| SCHEMBL2449442 | 0.86 | PPARA (0.45) | ALDH1A1PKMCTSSL3MBTL1 | |
| SCHEMBL3752133 | 0.82 | NFKB1 (0.30) | — | |
| SCHEMBL21065982 | 0.81 | KDM4E (0.47) | PKMACECTSSCTSLCTSK | |
| SCHEMBL4248574 | 0.80 | AAK1 (0.34) | CTSSCTSLCTSBCTSK | |
| SCHEMBL4253799 | 0.79 | — | — | |
| SCHEMBL8392929 | 0.78 | ATM (0.45) | PKMATMITGA4ITGB7ACE | |
| SCHEMBL11651226 | 0.78 | ATM (0.45) | PKMATMITGA4ITGB7ACE | |
| SCHEMBL9321962 | 0.78 | ATM (0.45) | PKMATMITGA4ITGB7ACE | |
| SCHEMBL2476924 | 0.77 | MMP13 (0.46) | ALDH1A1ATMITGA4ITGB7ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722629-B2 | Auristatin derivatives and use thereof | SEATTLE GENETICS, INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-20130157960-A1 | NOVEL AURISTATIN DERIVATIVES AND USE THEREOF | SEATTLE GENETICS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| EP-2084154-B1 | AMINOACYL PRODRUG DERIVATIVES AND MEDICAMENTS FOR TREATMENT OF THROMBOEMBOLIC DISORDERS | BAYER IP GMBH (DE) | 2012-11-21 | — | — | EP | disclosed |
| EP-2084154-A1 | AMINOACYL PRODRUG DERIVATIVES AND MEDICAMENTS FOR TREATMENT OF THROMBOEMBOLIC DISORDERS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008022786-A1 | AMINOACYL PRODRUG DERIVATIVES AND MEDICAMENTS FOR TREATMENT OF THROMBOEMBOLIC DISORDERS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130157960-A1 | NOVEL AURISTATIN DERIVATIVES AND USE THEREOF | AURKC, AURKA, AURKB | ALDH1A1 2774/4885PKM 3329/4885ATM 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.